#USA #Houston #Bob Smith #Iterion Therapeutics #Manuel Aivado

Iterion Therapeutics Strengthens Board

Iterion Therapeutics, a Houston-based clinical-stage oncology firm, has recently announced a significant enhancement to its board of directors by appointing two seasoned experts, Manuel Aivado, MD, PhD and Bob Smith. This decision is seen as a strategic move to bolster the company’s leadership at a crucial juncture as it pushes forward with the clinical development of its lead asset, tegavivint.

Advancing Oncology Treatments

Iterion Therapeutics specializes in developing innovative therapies aimed at targeting aberrant Wnt/β-catenin signaling pathways, which are crucial in various cancers. The appointment of Dr. Aivado and Mr. Smith comes at a pivotal time as the company works on its first-in-class small molecule inhibitor of TBL1, known as tegavivint. This compound is currently being investigated for its efficacy in treating hepatocellular carcinoma (HCC), with further explorations into its use against metastatic colorectal cancer (mCRC) and other cancers driven by Wnt signaling.

Dr. Rahul Aras, President and CEO of Iterion, expressed his excitement regarding these new appointments, stating, "Manuel and Bob bring exceptional expertise in clinical development, oncology drug advancement, company building, and strategic partnering at a pivotal moment for Iterion." Their addition is expected to streamline the development strategies for tegavivint across various indications, setting the company up for long-term success in addressing unmet needs in Wnt-driven cancers.

Profiles of the New Board Members

Manuel Aivado, MD, PhD has a rich history in oncology and clinical development, previously serving as President and CEO of Stelexis BioSciences. He has held dual roles at Aileron Therapeutics as CEO and CMO, where he led numerous investigational assets from early-stage development to market approval while working at Taiho and GSK. His wealth of experience in oncology drug development will be crucial for Iterion's strategic direction and growth.

Bob Smith brings a unique perspective as a Venture Partner at OrbiMed, paired with extensive leadership experience at Pfizer, where he served as Senior Vice President for its Global Gene Therapy business and led Business Development and Alliance Management. His strategic partnerships and commercialization expertise are expected to enhance Iterion’s collaborations and partnerships within the biotech sector.

The Role of Tegavivint

Tegavivint is notable for being the first small-molecule inhibitor targeting TBL1, which is pivotal for nuclear β-catenin stability and oncogenic gene expression. The compound disrupts the nuclear TBL1β-catenin complex, promoting the degradation of nuclear β-catenin and inhibiting cancer cell growth drivers, while protecting normal cellular functions, an aspect that distinguishes it from other treatments.

Clinical trials presented at the 2026 ASCO Annual Meeting revealed promising Phase 1 results in treating patients with advanced HCC exhibiting mutations that activate the Wnt pathway. These findings showcased the drug's tolerability, clinical benefit, and targeted pharmacodynamic activity, emphasizing the potential of tegavivint in various cancers.

Looking Ahead

Iterion Therapeutics is firmly establishing itself in the field of oncology drug development, supported by a focused clinical strategy centered on hepatocellular carcinoma and aimed at exploring further opportunities in Wnt-driven cancers, including pediatric osteosarcoma. The company has also garnered significant financial backing, having received $26 million in Product Development Awards from the Cancer Prevention and Research Institute of Texas (CPRIT).

By strengthening its board with such illustrious individuals, Iterion is poised for significant advancements in its pipeline and continued growth in the competitive market of oncology treatments. To learn more about their innovative therapeutic approaches, visit Iterion Therapeutics.